Roche to Acquire AI Diagnostics Firm PathAI for Up to $1B
BOSTON — Swiss pharmaceutical giant Roche has agreed to acquire PathAI, a Boston-based artificial intelligence diagnostics company, in a deal valued at up to $1 billion, according to a report this week from Fierce Biotech.
The acquisition targets PathAI’s machine learning tools for analyzing tissue samples and diagnosing disease.
PathAI specializes in AI-powered pathology, developing algorithms that assist clinicians in interpreting biopsy and tissue samples with greater speed and accuracy. The company’s technology platform uses deep learning to detect patterns in pathology slides that may be difficult for human pathologists to identify consistently.
For Roche, which already operates one of the world’s largest diagnostics businesses through its Roche Diagnostics division, the acquisition signals a strategic push to integrate artificial intelligence more deeply into its clinical diagnostics portfolio. The company has been expanding its digital pathology capabilities as hospitals and laboratories increasingly adopt AI-assisted tools.
Major pharmaceutical and diagnostics companies have increasingly acquired AI startups rather than building capabilities in-house. Enterprise investment in AI-powered medical imaging and diagnostics has grown in 2026.
PathAI’s Boston headquarters places it within one of the country’s most active biotech corridors. The acquisition represents foreign direct investment in American AI healthcare infrastructure at a time when US policymakers are closely monitoring cross-border technology deals.
The deal’s structure, with a value of “up to” $1 billion, may include milestone-based payments tied to performance or regulatory benchmarks, a common arrangement in biotech acquisitions.
Financial terms beyond the headline figure and the expected closing timeline were not immediately disclosed in the initial reporting.